Revvity Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? Revvity Inc trades at $110.1 (market cap $11.87B), while Vanguard Total World Stock Index Fund ETF trades at $156.32. The key difference: Revvity Inc pays a 0.26% dividend while Vanguard Total World Stock Index Fund ETF pays none, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Revvity Inc nearer its low. Which is the better fit depends on your goals.
| RVTY | VT | |
|---|---|---|
Market Cap | $11.87B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $117.75 | $159.35 |
52-Week Low | $82.26 | $128.41 |
Enterprise Value | $14.36B | — |
Dividend Yield | 0.26% | — |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Vanguard Total World Stock ETF (VT) trades at $154.29, down 0.32% on the day, with technical indicators showing a bearish bias despite neutral oscillators. The ETF provides diversified global equity exposure with over 10,000 stocks across developed and emerging markets. Recent news highlights institutional interest, with Alta Advisers Ltd increasing its position by 18.5% in Q1 2026 (SEC filing, 2026-07-21).
VT offers broad global diversification with a low 0.06% expense ratio, appealing for long-term investors seeking worldwide market exposure. Key risks include global economic volatility and currency fluctuations. The bearish technical signals suggest near-term pressure, but the fund's comprehensive coverage provides stability for portfolio construction.
Trailing returns across standard periods
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →